Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence.
Hemrajani
Reena H
RH
MS IV, Florida State University College of Medicine, Tallahassee, Florida, USA. rhemrajani@mcvh-vcu.edu
Kim
Kevin B
KB
Amos
Warren R
WR
Mann
David E
DE
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007107:Immune System; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D008954:Models, Biological; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins; D012074:Remission Induction; D055502:Secondary Prevention; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor